Rubicon Research was incorporated on May 6, 1999, as a private limited company under the Companies Act, 1956, under the name ‘Rubicon Consultants Private Limited’, pursuant to a certificate of incorporation issued by the RoC.
Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of seven listed Indian companies assessed by F&S, and the company), it is the only Indian pharmaceutical player with a complete focus on regulated markets.
The company’s multi-disciplinary, data-driven, and return on investment (ROI) centric product selection framework is geared towards identifying sustainable opportunities for new product development. It identifies and pursues such opportunities in a manner that provides it a competitive advantage by leveraging its development, manufacturing, and commercialization capabilities to create and grow its share of the market.
Business area of the company
Rubicon Research, incorporated in 1999, is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. Further, the company has robust sales and distribution capabilities in the US.
Products of the company
- Metoprolol Tartrate
- Cyclobenzaprine Hydrochloride
- Carbidopa-Levodopa
- Diclofenac Potassium
- Baclofen
- Rabeprazole Sodium
- Lidocaine Hydrochloride
- Tramadol Hydrochloride
History and milestones
- 2007: Received investment from Kotak India Venture Fund - I, Kotak India Venture Limited and Kotak Employees Investment Trust.
- 2011: Commencement of manufacturing of certain special drugs in Ambernath Manufacturing Facility.
- 2011: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility for tablet manufacturing and secondary packaging by Medicines and Healthcare Products Regulatory Agency, United Kingdom.
- 2013: Receipt of GMP clearance approval for Ambernath Manufacturing Facility from Department of Health and Ageing Therapeutic Goods Administration, Australian Government.
- 2014: Receipt of approval for its product i.e., ‘metoprolol tartrate tablets’ from the Food & Drug Administration, United State of America.
- 2016: Acquisition of majority stake by ECP III Pte Ltd.
- 2017: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility from the Ministerio De Sandidad, Servicios Sociales E Igualdad, Spain.
- 2019: Acquisition of majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd.
- 2019: Acquisition of Impopharma Canada Limited by Rubicon Research Canada Limited
- 2021: Acquired the business of Meditab Specialities Limited on a slump sale basis.
- 2022: Set up own sales and marketing front end in US via its Material Subsidiary.
- 2023: Receipt of certificate of GMP compliance for Satara Manufacturing Facility of non-sterile liquid drug manufacturer and pre-approval coverage provided for non-sterile liquid product by US FDA.
- 2024: Acquisition of Validus Pharmaceuticals LLC.
- 2024: ANDA pre-approval drug inspection of nasal spray block at Ambernath Manufacturing Facility by USFDA.
- 2024: Receipt of supplement approval for Thane R&D Facility as a testing site of drug substance - lead test from USFDA.
- 2024: Received USFDA establishment inspection report for Ambernath Manufacturing Facility.
- 2024: Commencement of manufacturing of nasal products at Ambernath Manufacturing Facility.
- 2025: Received new drug application approval from USFDA for Lopressor (Metoprolol Tartrate) oral solution.
- 2025: Received USFDA establishment inspection report for Thane R&D Facility.
- 2025: Acquisition of Pithampur Manufacturing Facility from Alkem Laboratories Limited.
- 2025: Acquisition of AIM RX 3PL LLC.